Betulinic acid (BA), a lupane-type triterpene widely studied for its selective cytotoxicity against malignancies [], shows synergistic pro-apoptotic activity when combined with blockade of anti-apoptotic B-cell lymphoma-2 (BCL-2) proteins, key targets of mitochondrial integrity in cancer cells []. Guided by this rationale, we assembled a virtual library of BA hybrids by covalently linking the triterpene scaffold to natural molecules with reported antioxidant and anticancer activities. After physicochemical and drug-likeness filtering, the candidates were docked into the BH3-binding groove of BCL-2 (PDB ID: 4LVT), BCL-XL (PDB ID: 2YXJ), and the chimeric receptor BCL2-XL (PDB ID: 2W3L). Two hybrids, BA-Celastrol and BA-Proanthocyanidin B2, emerged with docking scores of −13.0 kcal/mol and −12.5 kcal/mol, respectively, against chimeric BCL2-XL (2W3L); −10.7 and −10.2 kcal/mol, respectively, against BCL-XL (2YXJ); and −9.3 and −8.7 kcal/mol, respectively, on BCL-2 (4LVT), outperforming the parent compound BA in each case. Molecular-mechanics/Poisson–Boltzmann surface area calculations and 100 ns molecular dynamics simulations confirmed stable complexes. In silico Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiling predicted favorable profiles for both compounds. Collectively, these findings highlight BA-Celastrol and BA-Proanthocyanidin B2 as a promising dual BCL-2/BCL-XL that can be further synthesized and biologically assessed for experimental validation.
Author Contributions
Conceptualization, M.M. and E.P.A.; methodology, E.P.A.; software, M.M.; validation, M.M., C.Ș. and E.P.A.; formal analysis, M.M.; investigation, E.P.A.; resources, C.Ș.; data curation, E.P.A.; writing—original draft preparation, E.P.A.; writing—review and editing, M.M.; visualization, E.P.A.; supervision, C.Ș.; project administration, M.M.; funding acquisition, M.M. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
The original contributions presented in the study are included in the manuscript, further inquiries can be directed to the corresponding author.
Conflicts of Interest
The authors declare no conflict of interest.
References
- Wang, K.; Shang, J.; Tao, C.; Huang, M.; Wei, D.; Yang, L.; Yang, J.; Fan, Q.; Ding, Q.; Zhou, M. Advancements in betulinic acid-loaded nanoformulations for enhanced anti-tumor therapy. Int. J. Nanomed. 2024, 19, 14075–14103. [Google Scholar] [CrossRef] [PubMed]
- Croce, C.M.; Vaux, D.; Strasser, A.; Opferman, J.T.; Czabotar, P.E.; Fesik, S.W. The BCL-2 protein family: From discovery to drug development. Cell Death Differ. 2025, 32, 1369–1381. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).